Evigrade
DrugsCosmetic ingredientsCalculatorsInteractionsEvigrade SkinEvigrade Meds ↗
ConditionsJournalMethodologyPro for practitioners
ESRU

Risedronic acid

AEMPS

Nitrogen-containing bisphosphonate

ATC code: M05BA07

Brand names: Risedronato Cinfa, Actonel, Acrel, Risedronato Normon

Updated · Methodology

Indications

A

Postmenopausal osteoporosis

First line

First-line for postmenopausal osteoporosis per AACE/ACE 2020 and SEIOMM 2024 alongside alendronate. Cuts vertebral fracture risk by 41%, hip fracture by 39% (VERT). Standard dose 35 mg weekly. Reassess at 5 years (drug holiday). Also indicated in glucocorticoid-induced osteoporosis on long-term prednisolone 7.5 mg or more.

Sources

  1. AEMPS: Ficha técnica de Ácido risedrónico (2024)
  2. Cochrane Database of Systematic Reviews: Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women (2022)
  3. Endocrine Society: Postmenopausal Osteoporosis Treatment Guidelines (2019)
  4. JAMA: Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis: A Randomized Controlled Trial (1999)

ICD-10: M81.0 · ICD-11: FB83.11

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

F

Anti-aging and longevity

Not recommended

Risedronic acid is a second-generation bisphosphonate. It is prescribed for osteoporosis with confirmed reduced bone density, Paget's disease, and glucocorticoid-induced osteoporosis (NOGG 2021, AACE 2020). In anti-aging circles, risedronate is promoted for anti-aging bone strengthening in healthy perimenopausal women without diagnosed osteoporosis. In people without confirmed osteoporosis, no clinical studies of prophylactic use exist. The drug has serious adverse effects: esophageal erosions and ulcers (requires intake with plenty of water in upright position), osteonecrosis of the jaw, and atypical femoral fractures on long-term use. If risedronate was prescribed without confirmed osteoporosis, consider seeking a second opinion.

Sources

  1. AEMPS: Ficha técnica de Ácido risedrónico (2024)
  2. Cochrane: Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (2012)
How to read tiers A–F
  • AStrong evidence – first or second line in international guidelines
  • BRecommended in selected cases
  • CStudy data contradict each other
  • DBenefit not proven, no documented harm
  • FDocumented harm, or risk without benefit

Mechanism of action

Incorporated into bone hydroxyapatite and taken up by osteoclasts during resorption. Inhibits farnesyl pyrophosphate synthase, disrupts protein modification, and induces osteoclast apoptosis. Compared with alendronate, more convenient dosing (35 mg weekly or 75 mg twice monthly or 150 mg monthly) and lower esophagitis rate. Effect persists for years – bone half-life is several years.

Safety

Contraindications

  • Bisphosphonate hypersensitivity
  • Hypocalcemia
  • Esophageal abnormalities (achalasia, stricture) or inability to stay upright for 30 minutes
  • Severe renal impairment (eGFR under 30)
  • Pregnancy and lactation

Serious adverse effects

  • Severe esophagitis and esophageal ulcers (with incorrect intake)
  • Osteonecrosis of the jaw (rare, higher around dental procedures)
  • Atypical femoral fractures (after 5 years)
  • Severe hypocalcemia
  • Hypersensitivity reactions

Common adverse effects

  • Abdominal pain, reflux, esophagitis
  • Muscle, bone, joint pain
  • Headache
  • Mild hypocalcemia

Pregnancy: can you take Risedronic acid?

Bisphosphonates accumulate in the skeleton for years. Pregnancy use is contraindicated.

Practical notes

Timing and administration

Take strictly on empty stomach immediately on waking with a glass of plain water (≥200 mL). Do not lie down for 30–60 minutes – esophagitis risk. Breakfast, other medications, calcium, and vitamin D – at least 30 minutes later. Mineral water, coffee, tea, juice reduce absorption – avoid. All patients also take calcium 1000–1200 mg and vitamin D 800–1000 IU daily.
Label mentions3 mentions

Verbatim lines from the interaction sections, in the language of the label

From this drug’s label

  • Moderateantineoplásicosclass named in the label
    «Osteonecrosis de mandíbula: Antes de iniciar el tratamiento con bifosfonatos en pacientes con factores concomitantes de riesgo (por ejemplo, cáncer, quimioterapia, radioterapia, corticoides o poca…»

    AEMPS, section 4.4 · Open on CIMA

  • Moderatecorticosteroidesclass named in the label
    «Osteonecrosis de mandíbula: Antes de iniciar el tratamiento con bifosfonatos en pacientes con factores concomitantes de riesgo (por ejemplo, cáncer, quimioterapia, radioterapia, corticoides o poca…»

    AEMPS, section 4.4 · Open on CIMA

  • AINEclass named in the label
    «No se han realizado estudios específicos de interacción, sin embargo no se han observado interacciones clínicamente relevantes con otros medicamentos durante los ensayos clínicos. En los estudios de…»

    AEMPS, section 4.5 · Open on CIMA

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Summary of a multi-drug list →

Medicine list: everything you take in one place →

Frequently asked

What is Risedronic acid used for?

Risedronic acid is evaluated for the following indications with varying evidence strength: Postmenopausal osteoporosis (evidence tier A), Anti-aging and longevity (evidence tier F). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Risedronic acid?

Common side effects of Risedronic acid (≥ 1 in 100): Abdominal pain, reflux, esophagitis, Muscle, bone, joint pain, Headache, Mild hypocalcemia. See the Safety section for uncommon and serious reactions.

Is Risedronic acid safe during pregnancy?

Bisphosphonates accumulate in the skeleton for years. Pregnancy use is contraindicated.

Is Risedronic acid compatible with breastfeeding?

Limited data. Not used during lactation.

Who should not take Risedronic acid?

Risedronic acid is contraindicated in: Bisphosphonate hypersensitivity; Hypocalcemia; Esophageal abnormalities (achalasia, stricture) or inability to stay upright for 30 minutes; Severe renal impairment (eGFR under 30); Pregnancy and lactation. Full list in the Safety section.

Official sources

Direct links to regulator labels. Open in a new tab.

Other drugs in this group

Alendronic acid, Denosumab